CD274 and non-small cell lung carcinoma: A low dose and high dose of PDC*lung01 was administered to either patients with stage II/IIIA NSCLC in the adjuvant setting or in patients with stage IV NSCLC, PD-L1 ≥ 50% with no targetable mutation in the first-line setting.